Teva has introduced a reformulated version of levothyroxine, including two previously unavailable strengths (12.5mcg and 75mcg) that are exclusive to the company.

Authorised for the control of hypothyroidism, congenital hypothyroidism in infants, acquired hypothyroidism in children and juvenile myxedema, the drug is available in the following strengths and pack sizes:

  • 12.5mcg tablets x 28
  • 25mcg tablets x 28
  • 50mcg tablets x 28
  • 75mcg tablets x 28
  • 100mcg tablets x 28.

Bruno Barcelos, senior director, generics, said: “The addition of the exclusive strengths 12.5mcg and 75mcg helps deliver on our commitment to addressing unmet patient needs – and we hope it makes a positive impact on the lives of patients living with underactive thyroid issues.”

The formulation is also lactose- and galactose-free. Underactive thyroid affects 15 in every 1,000 women and one in 1,000 men.

Originally Published by Pharmacy Magazine

We Recommend

Trouble in paradise

Millions of Britons will be jetting off this summer, but thousands are putting themselves at risk by being unprepared

Dieters need to be realistic and take their time

‘People need to build at it and cut down slowly,’ believes XLS-Medical dietician, Jodie Relf

Popular Features

Does your pharmacy comply with the Equality Act 2010?

The Equality Act 2010 (the ‘Act’) consolidated previous legislation concerning a range of discrimination including o...

Call for GPs and pharmacists need to meet up more

Closer working with GPs to move some of the workload over to pharmacy can only be done through communication

Promote men’s health and boost your business

Despite many targeted health campaigns over the years, primary healthcare services – including pharmacies – are stil...